Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
Giancarlo ComiRaed AlroughaniAaron L BosterAnn D BassRegina BerkovichÓscar FernándezHo Jin KimVolker LimmrothJan N LyckeRichard Al MacdonellBasil SharrackBarry A SingerPatrick VermerschHeinz WiendlTjalf ZiemssenAlan JacobsNadia DaizadehClaudio E RodriguezAnthony Traboulseenull nullPublished in: Multiple sclerosis (Houndmills, Basingstoke, England) (2019)
Additional alemtuzumab courses significantly improved outcomes, without increased safety risks, in CARE-MS patients with continued disease activity after Course 2. How this compares to outcomes if treatment is switched to another DMT instead remains unknown.
Keyphrases
- disease activity
- multiple sclerosis
- systemic lupus erythematosus
- rheumatoid arthritis
- mass spectrometry
- rheumatoid arthritis patients
- healthcare
- ms ms
- ankylosing spondylitis
- palliative care
- juvenile idiopathic arthritis
- quality improvement
- pain management
- combination therapy
- climate change
- chronic pain
- weight loss
- human health